Kite Pharma Inc. (KITE) 71.88 $KITE Biotech NantKwest

New Post Public Reply Private Reply Replies (0) Message Board

Jul 28, 2015 at 3:06 PM

Kite Pharma Inc. (KITE) 71.88 $KITE

Biotech NantKwest Stock Surges On 1st Day Of Trading
at Investor's Business Daily - 2 hrs 58 mins ago
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 71.88 (+3.02), NK: 35.94 (+35.94), ALXN: 202.58 (+4.48), RCPT: 227.95 (+0.86), AMGN: 174.44 (+8.90), JUNO: 48.63 (+0.83), CELG: 135.89 (+3.33)

Biotech IPO Boom Gaining Thrust With NantKwest Debut
at Investor's Business Daily - Fri Jul 24, 5:33PM CDT
A hot market for biotech IPOs is about to get hotter with the upcoming debut of NantKwest, a developer of cancer therapies that could set a record for market valuation. NantKwest (NK) will be the 51st initial public offering in the health care field...
BBP: 36.17 (+0.69), BIIB: 319.35 (+9.92), BBC: 36.62 (+0.44), ADRO: 26.85 (+0.45), KITE: 71.88 (+3.02), NK: 35.94 (+35.94), ALXN: 202.58 (+4.48), RCPT: 227.95 (+0.86), TEVA: 70.95 (-1.05), JUNO: 48.63 (+0.83), CELG: 135.89 (+3.33)

3 IPOs That Are Getting Strong Investor Attention
at Investor's Business Daily - Wed Jul 15, 11:48AM CDT
With strong investor demand for shares, ProNAi Therapeutics (DNAI) raised the expected price of its initial public offering, which is scheduled to price after the close Wednesday. ProNAi is among three of the eight IPOs out this week that are...
RPD: 24.70 (+1.00), CYBR: 59.84 (+0.01), KITE: 71.88 (+3.02), OLLI: 19.67 (-0.30), DNAI: 26.93 (+0.90), QLYS: 36.96 (-0.17), JUNO: 48.63 (+0.83)

'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 95.21 (+1.04), FBT: 126.41 (+2.56), XBI: 257.68 (+5.90), AMGN: 174.44 (+8.90), IBB: 382.22 (+8.64), INTC: 29.01 (+0.66), CELG: 135.89 (+3.33), NFLX: 107.28 (+0.85), SPY: 209.25 (+2.46), GILD: 112.37 (+1.83), KITE: 71.88 (+3.02), RCPT: 227.95 (+0.86), JUNO: 48.63 (+0.83), TWTR: 36.15 (+1.45), AAPL: 123.81 (+1.04), Z: 79.46 (+2.55)

Critical Alerts For Cliffs Natural Resources, JD.com, Kite Pharma, JetBlue and Amazon.com Released By InvestorsObserver
PR Newswire - Tue Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CLF, JD, KITE, JBLU and AMZN.
AMZN: 526.45 (-4.96), KITE: 71.88 (+3.02), JBLU: 22.90 (+0.55), CLF: 3.04 (+0.64), JD: 32.30 (+0.15)

Trader's Notebook: Can Chevron Maintain Its High Yield?
at The Street - Tue Jul 14, 8:00AM CDT
Look under the hood when considering when to make a play for higher yielding names.
KITE: 71.88 (+3.02), CVX: 92.40 (+3.26)

5 Stocks Ready for Breakouts -- Must-See Charts
at The Street - Fri Jul 10, 8:35AM CDT
These stock charts look ready to break out and trade higher from current levels.
VSTM: 7.64 (+0.49), KITE: 71.88 (+3.02), GKOS: 29.86 (-0.75), AMRN: 2.13 (-0.03), CTCT: 25.10 (-0.38)

3 Biotech Stocks Working On CAR-T Immunotherapy You Ought To Watch
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 06, 12:02PM CDT
Source: Juno Therapeutics. Last week, Celgene Corp. shocked biotech investors when it agreed to pay $1 billion for $850 million worth of Juno Therapeutics ' stock and a handful of licensing rights, leaving Celgene with a 10% stake in the...
ZIOP: 12.46 (+0.43), KITE: 71.88 (+3.02), JUNO: 48.63 (+0.83), CELG: 135.89 (+3.33)

InsiderInsights.com Daily Round Up 7/2/15: NHF, VISI, NXRT, ATLS
InsiderInsights - at Seeking Alpha - Sat Jul 04, 11:54AM CDT

LBTYK: 48.58 (+0.37), TACO: 15.50 (-0.72), ATLS: 3.14 (+0.28), GIII: 69.39 (+0.23), VISI: 9.63 (+0.13), NXRT: 12.82 (-0.34), ALRM: 17.16 (+0.01), TRU: 24.47 (+0.08), W: 37.45 (+0.29), LVLT: 52.82 (+0.72), PDVW: 30.40 (-1.27), COF: 78.58 (-0.03), KITE: 71.88 (+3.02), APPF: 14.73 (+0.58), CPLA: 50.38 (-2.50), HRG: 13.59 (+0.05), JUNO: 48.63 (+0.83), TWTR: 36.15 (+1.45)

Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 159.57 (+0.08), KITE: 71.88 (+3.02), ADMS: 26.74 (+0.59), ACHN: 8.39 (+0.11)

Celgene: The Juno Therapeutics Deal Is Worth The Premium
LN Investors - at Seeking Alpha - Wed Jul 01, 3:04PM CDT

KITE: 71.88 (+3.02), AMGN: 174.44 (+8.90), JUNO: 48.63 (+0.83), CELG: 135.89 (+3.33), NVS: 102.74 (+1.20)

Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs
GlobeNewswire - Wed Jul 01, 7:00AM CDT
Kite Pharma, Inc., (Nasdaq:KITE) and The Leukemia & Lymphoma Society (LLS) announced today that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.
KITE: 71.88 (+3.02)

'Fast Money' Recap: Greece's Uncertain Future Extends to U.S. Stocks
at The Street - Wed Jul 01, 4:00AM CDT
The trading panel discussed Puerto Rico, European stocks and whether Facebook will buy Twitter.
FIT: 45.35 (+1.42), SPY: 209.25 (+2.46), NKE: 113.35 (+1.62), KITE: 71.88 (+3.02), GILD: 112.37 (+1.83), FB: 95.21 (+1.04), DB: 33.18 (+0.47), GOOGL: 658.70 (+0.43), KORS: 39.42 (+0.35), TWTR: 36.15 (+1.45), AAPL: 123.81 (+1.04)

Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 159.57 (+0.08), KITE: 71.88 (+3.02), CLLS: 36.24 (+1.37), JUNO: 48.63 (+0.83), CYAD: 56.84 (+0.10), CELG: 135.89 (+3.33)

Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.14 (-0.05), NFLX: 107.25 (+0.82), BLUE: 159.57 (+0.08), AMZN: 526.45 (-4.96), TSLA: 264.14 (+11.13), KITE: 71.88 (+3.02), LBIO: 8.84 (+0.05), JUNO: 48.63 (+0.83), EGRX: 92.23 (+1.00)

A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.14 (-0.05), NFLX: 107.25 (+0.82), BLUE: 159.57 (+0.08), AMZN: 526.45 (-4.96), TSLA: 264.14 (+11.13), KITE: 71.88 (+3.02), LBIO: 8.84 (+0.05), JUNO: 48.63 (+0.83), EGRX: 92.23 (+1.00)

Why Juno Therapeutics Stock Soared Today
George Budwell, The Motley Fool - Motley Fool - Tue Jun 30, 10:35AM CDT
What : Shares of the clinical-stage biopharma Juno Therapeutics jumped by 33% on exceptionally high volume today after the company announced a 10-year licensing agreement with Celgene Corp. for its CAR-T and TCR drug development platform. Per...
NBL: 35.50 (+0.77), KITE: 71.88 (+3.02), AZN: 32.85 (+0.14), JUNO: 48.63 (+0.83), CELG: 135.89 (+3.33)

I Don't Believe This Correction Is Over
at The Street - Tue Jun 30, 9:20AM CDT
There just is no certainty and there's very little trust.
SGYP: 8.14 (-0.05), NFLX: 107.25 (+0.82), BLUE: 159.57 (+0.08), AMZN: 526.45 (-4.96), TSLA: 264.14 (+11.13), KITE: 71.88 (+3.02), LBIO: 8.84 (+0.05), JUNO: 48.63 (+0.83), EGRX: 92.23 (+1.00)

Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT

FIT: 45.35 (+1.42), PIRS: 3.23 (+0.04), KITE: 71.88 (+3.02), SRPT: 32.12 (+0.12), WSH: 46.29 (+0.26), CALA: 8.15 (-0.28), CLLS: 36.24 (+1.37), LBIO: 8.84 (+0.05), JUNO: 48.63 (+0.83), PNR: 59.35 (+0.60), APOL: 13.44 (+0.09), DSKX: 3.21 (-0.10)

Stock Futures Take A Firm Bounce; Monster, Soufun Set To Rebound
at Investor's Business Daily - Tue Jun 30, 8:08AM CDT
Stock futures headed firmly higher ahead of Tuesday's open, leaning toward a rebound from Monday's steep losses. Dow futures were rising, 107.7 points above fair market value. Nasdaq 100 futures were up a solid 28.6 points. S&P 500 futures climbed...
LEJU: 6.86 (+0.04), MNST: 149.53 (+0.77), KITE: 71.88 (+3.02), CLLS: 36.24 (+1.37), CMCM: 27.15 (+0.97), SFUN: 6.77 (+0.01), JUNO: 48.63 (+0.83), TASR: 31.03 (+0.70), CGIX: 10.07 (+0.20), CELG: 135.89 (+3.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...